# OnCo record paper-p013-pertuzumab-biosimilar-bmc-cancer-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-p013-pertuzumab-biosimilar-bmc-cancer-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-p013-pertuzumab-biosimilar-bmc-cancer-2022" ;
  schema:name "Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial"@en ;
  schema:description "A phase 3 trial in Iran found that a locally made copy of pertuzumab, given before surgery, cleared tumours from the breast as often as the original."@en ;
  schema:url <https://onco.cc/key-papers/paper-p013-pertuzumab-biosimilar-bmc-cancer-2022/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1186/s12885-022-09895-5>, <https://pubmed.ncbi.nlm.nih.gov/36071409/>, <https://doi.org/10.1186/s12885-022-10455-0> ;
  schema:sameAs <https://doi.org/10.1186/s12885-022-09895-5> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Allahyari A, Ehsanpour A, Najafi B, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/cinnagen/> ;
  onco:terms <https://onco.cc/terms/biosimilar/> ;
  onco:trials <https://onco.cc/trials/nct04957212/> .